Health Catalyst, INC

Health Catalyst announced the sale of its Vitalware business unit to Med-Metrix for $147 million, aiming to accelerate its strategic transformation and focus on AI and core technology.

Health Catalyst announced first quarter 2026 financial results, with revenue and adjusted EBITDA surpassing expectations, alongside a strategic operating model transformation.

Health Catalyst is reducing its global workforce by approximately 9% as part of a strategic initiative to streamline operations and focus on core technology opportunities.

Health Catalyst, a healthcare data and analytics provider, reported mixed financial results for Q4 and full year 2025, with revenue growth but significantly increased net losses and a substantial goodwill impairment.

Health Catalyst, Inc. announced that Chief Commercial Officer Kevin Freeman will transition from his role on February 1, 2026, to become a senior advisor.

Health Catalyst, Inc. announced preliminary unaudited 2025 financial results, exceeding revenue guidance and meeting Adjusted EBITDA targets, alongside strategic updates for 2026.

Health Catalyst Inc. reported a significant increase in net loss for Q1 2026, primarily due to a $95.5 million goodwill impairment, while total revenue decreased year-over-year.

Health Catalyst reports a widened net loss in Q3 2025, driven by a significant goodwill impairment charge and restructuring costs, despite technology revenue growth.

Health Catalyst, Inc. reported a significantly wider net loss in Q2 2025, primarily driven by a substantial goodwill impairment charge, despite modest revenue growth.

Health Catalyst's Q1 2025 revenue increased by 6% year-over-year, driven by technology subscriptions, while the company continues to navigate a challenging macroeconomic environment and strategic restructuring.

Health Catalyst's Q3 2024 results show a 3% increase in revenue compared to the same period last year, alongside a reduced net loss.

Health Catalyst's second quarter 2024 results show stable revenue and a reduction in net losses compared to the same period last year.

Health Catalyst, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding executive compensation, corporate governance, and director information.

Health Catalyst, Inc. reported a significant net loss of $178.0 million in 2025, primarily driven by a $105.4 million goodwill impairment, despite a modest 1% revenue increase to $311.1 million.

Health Catalyst files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and accountant fees.

Health Catalyst's 2024 10-K filing reveals a year of revenue growth amidst ongoing macroeconomic challenges and strategic restructuring.

Health Catalyst has filed an amendment to its annual report to correct omissions in certifications related to internal control over financial reporting.

Health Catalyst, Inc. released its 2023 10-K filing, outlining its financial results, strategic initiatives, and risk factors.

Green Jill Hoggard, a Director of Health Catalyst, Inc., received 80,691 shares of common stock on July 16, 2026.

Julie Larson-Green, a Director of Health Catalyst, Inc., received 80,691 shares of common stock on July 16, 2026.

Steven H Nelson, a Director of Health Catalyst, Inc., received 80,691 shares of common stock on July 16, 2026.

Justin Spencer, a Director of Health Catalyst, Inc., received 80,691 shares of common stock on July 16, 2026.

Health Catalyst CEO Albert Benjamin reported a transaction involving the sale of 34,485 shares to cover tax withholding obligations upon the vesting of restricted stock units.

CEO Benjamin Albert disposed of 336 shares of Health Catalyst, Inc. to satisfy tax withholding obligations.

Health Catalyst, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 16, 2026, to be held virtually.

Health Catalyst is holding its 2025 Annual Meeting of Stockholders on July 9, 2025, to vote on director elections, auditor ratification, executive compensation, and a proposal to declassify the board.

Health Catalyst, Inc. has filed a definitive proxy statement with the SEC.

Health Catalyst's proxy statement details the agenda for the 2024 Annual Meeting of Stockholders, including director elections, auditor ratification, and executive compensation approval.

Whetstone Capital Advisors and David Atterbury report a 4.5% beneficial ownership stake in Health Catalyst, Inc. through an amended Schedule 13D filing.

First Light Asset Management and Mathew P. Arens filed an amended Schedule 13D, disclosing their updated beneficial ownership of Health Catalyst, Inc. common stock and recent open market sales.

Activist investor Whetstone Capital Advisors, holding a 7.4% stake in Health Catalyst, proposes significant corporate governance reforms including board declassification and CEO/Chair separation.

First Light Asset Management and Mathew P. Arens disclose significant beneficial ownership in Health Catalyst, Inc., with Mr. Arens joining the board.

Impax Asset Management Group plc and its subsidiary Impax Asset Management LLC have reported beneficial ownership of 5.4% of Health Catalyst, Inc. common stock as of June 30, 2026.

Clint D. Coghill and associated entities have filed an amended Schedule 13G reporting an 8.6% beneficial ownership stake in Health Catalyst, Inc.

The Vanguard Group has filed an amended Schedule 13G, indicating 0% beneficial ownership in Health Catalyst Inc. following an internal realignment.

Whetstone Capital Advisors and David Atterbury have disclosed a 5.3% beneficial ownership stake in Health Catalyst, Inc. as of December 31, 2025.

Clint D. Coghill and affiliated entities have reported a combined beneficial ownership of 5.5% in Health Catalyst, Inc. common stock.

First Light Asset Management and its managing member, Mathew P. Arens, reported a combined beneficial ownership of 19.75% in Health Catalyst, Inc. common stock as of September 30, 2025.